Synthetic THC And Blood Pressure
Effects Of Cannabis Products On Blood Pressure Control
1 other identifier
interventional
50
1 country
1
Brief Summary
To investigate the effects of Dronabinol use on blood pressure and neurovascular physiology
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Feb 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 13, 2025
CompletedFirst Posted
Study publicly available on registry
November 17, 2025
CompletedStudy Start
First participant enrolled
February 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
January 12, 2026
January 1, 2026
1.8 years
November 13, 2025
January 9, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Blood Pressure
Blood pressure is the force exerted by circulating blood on the walls of the arteries as it is pumped through the body. Blood pressure will be measured as a ratio of systolic/diastolic (mmHg).
Baseline, 30 days
Heart Rate
Heart Rate is the number of contractions (beats) that the heart makes per minute. This will be measured in bpm (beats per minute)
Baseline, 30 days
Secondary Outcomes (4)
Baroreflex Sensitivity
Baseline, 30 days
Sympathetic control
Baseline, 30 days
Flow Mediated Dilation
Baseline, 30 days
Aortic Wave Reflection
Baseline, 30 days
Study Arms (2)
Dronabinol Group
ACTIVE COMPARATORPatients taking Dronabinol first and Placebo second
Placebo Group
ACTIVE COMPARATORPatients taking Placebo first and Dronabinol second
Interventions
Eligibility Criteria
You may qualify if:
- Recreational occasional Cannabis use (Consuming THC less than 2 times a week)
- years of age
- Biological male or female
You may not qualify if:
- BMI \> 35 kg/m2
- Diagnosed psychiatric disorders
- Hypotension
- History of seizures
- History of substance abuse or recreational drug use or positive urine drug screen
- History of uncontrolled disease including:
- Cardiovascular
- Pulmonary
- Gastrointestinal
- Pancreatic
- Hepatic
- Renal
- Hematological
- Endocrine (including Type I Diabetes)
- Neurological
- +6 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Study Sites (1)
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Virend Somers
Mayo Clinic
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 13, 2025
First Posted
November 17, 2025
Study Start
February 1, 2026
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
January 12, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share